Drug-Eluting Stent Payment Based On U.K. Price Sets Precedent – MedPAC
Executive Summary
The Medicare Payment Advisory Commission is wary of the potential precedent set by the Centers for Medicare & Medicaid Services' decision to reimburse for drug-eluting stents based on overseas prices
You may also be interested in...
“Value-Based” Reimbursement: Is Aranesp Decision Future Medicare Model?
The Centers for Medicare & Medicaid Services' "functionally equivalent" determination for Aranesp versus Procrit may be a useful model for value-based purchasing by Medicare in the future, a report by the Medicare Payments Advisory Commission suggests
“Value-Based” Reimbursement: Is Aranesp Decision Future Medicare Model?
The Centers for Medicare & Medicaid Services' "functionally equivalent" determination for Aranesp versus Procrit may be a useful model for value-based purchasing by Medicare in the future, a report by the Medicare Payments Advisory Commission suggests
J&J Wants Changes To Medicare OPPS Rule; Procrit Could Benefit
Johnson & Johnson is hoping for changes in the proposed 2003 Medicare Outpatient Prospective Payment System that would even out reimbursement differences between Procrit (epoetin) and Amgen's Aranesp (darbepoetin)